StockWatch
·

EXIDE INDUSTRIES LTD. Q2 FY27 Results

EXIDEINDQ2 FY27 Results
Filing
Result:Very Good· Market: Surged#Margin expansion#Cost led

Outlook: Optimistic · Guidance: None

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue5.3K4.3%21.3%
Total Income5.3K4.0%20.7%
Expenditure4.9K3.1%17.9%
PBT423.2913.0%67.2%
Net Profit287.1418.3%65.4%
OPM10.61%0.63pp1.64pp
NPM5.38%0.94pp1.45pp
EPS3.3718.2%66.8%
View full financials

Core revenue grew a strong 21.2% YoY with PAT up 65.4% on genuine margin expansion (OPM +165bps, NPM +145bps) from cost optimization and pricing rather than one-offs, making this a standout quarter for the auto ancillary/battery space even with EESL's gigafactory ramp-up loss trimming the consolidated beat versus standalone.

EXIDE INDUSTRIES · Q2 FY27 · THE VERDICT

Core Delivers, Lithium Delays; The Margin Question Lingers

Q2 revenue and PAT soared on a YoY basis—21% and 65% respectively—validating management's core growth narrative. But sequentially, profit fell 18%, margins missed guidance by 150 bps, and the lithium ramp slipped to Q4/FY28. The tension: solid momentum offset by near-term headwinds.

10 Nov 2026 · 6 min read
Q2 Revenue

₹5,292 Cr

+21.2% YoY; -4.3% QoQ

Q2 PAT

₹287 Cr

+65.4% YoY; -18.3% QoQ

EBITDA Margin

12.1%

+130 bps YoY

OPM Delivered

10.6%

vs 12–12.5% guided

The year-on-year numbers paint a confident picture. Core battery revenue is up 21%; profit up 65%. Exide's core business is firing—OEM traction strong, pricing power holding, exports ramping. Management's mid-double-digit growth guidance is not just met; it's credibly beaten. But a quarter is not a year. Sequentially, revenue fell 4%, profit fell 18%, and operating margin came in 150 bps below the stated 12–12.5% corridor. The lithium-ion ramp, positioned as the long-term growth engine, has slipped from implicit prior expectations into Q4/FY28. Strip away the momentum narrative and you see a company managing near-term margin pressure, sequential cyclicality, and execution risk on a ₹5,352 Crore investment that hasn't yet moved the needle on earnings.

The Core Business Delivered; Margins Didn't

EBITDA margin expanded 130 bps YoY to 12.1%, a headline-friendly number. But the delivered OPM of 10.6% against a stated corridor of 12–12.5% tells a different story. Management's explanation: price hikes announced in January and October have not yet flowed through. Lead and LME prices remain elevated; crude oil spiked (pushing separator costs); the rupee weakened. The lag between input spikes and pricing pass-through is typically one to two quarters. This means Q3 and Q4 could see margin pressure if commodities don't ease—and management has already hedged expectations, saying the corridor is a range, with some quarters at the lower end. The company is signalling it will remain within 12–12.5%, but not necessarily comfortable within it.

Q2 FY27, ₹ Cr
-28.346.2540.8575.4421.2Revenue YoY-4.3Revenue QoQ65.4PAT YoY-18.3PAT QoQ
Year-on-year growth masks sequential weakness. The -4.3% revenue and -18% profit decline suggest cyclicality or seasonal base effects (management blamed GST normalization post-boom) that could repeat in Q3.

Lithium: The Future, Deferred

Exide's 6 GWh lithium-ion plant came live in September 2026—on schedule. Two lines are operational: a 1.5 GWh NMC cell line and a 1.5 GWh LFP line. The company is now in sample and validation phase with multiple OEM partners (Tata Siern, MG, auxiliary battery suppliers, unnamed telecom players). But the critical issue is timing: management deferred major OEM production ramp to Q4 FY27 (January–March) or Q1 FY28 (April–June). This is a material slip from implicit prior expectations. Worse, the MD clarified that OEM lifecycle testing cycles run 2–3 years, and once lifecycle is complete, customers conduct pack-level and vehicle-level testing. Translation: the ₹1,400 Crore capex spend is now a 2–3 year story for ROI, not a 1–2 year one. On the call, analysts pressed hard on lithium margins, capex payback, and phase-2 timing. Management deferred all quantified guidance to the next quarter, citing pending board approval. The takeaway: Exide is building lithium at scale, but the money won't move the needle on earnings until late FY28 at earliest.

Management's claims vs. what holds up

Core business delivered mid-double-digit growth

Q2 revenue +21.2% YoY (H1 +18.9% YoY). Claim supported.

Supported

EBITDA margin expanded 130 bps to 12.1%

Delivered 12.1% EBITDA margin; but OPM only 10.6% vs 12–12.5% guided corridor.

Partially overstated

Margin corridor target 12–12.5% will be maintained

Q2 OPM 10.6% missed. MD now hedges: 'some quarters lower, some higher' within corridor.

Contradicted

Lithium revenue will materialize Q4 FY27 / Q1 FY28 for major OEMs

Small OEM samples Q3; major OEM production ramp deferred to Q4/Feb (pushed 2–3 quarters from prior implicit timeline).

Supported (but delayed)

Auto OEM business +25% for fourth consecutive quarter

Q2 overall revenue +21.2% YoY; OEM segment not separately broken out in result. Directional claim credible.

Supported

What Changed on This Call

Lithium timeline slipped. Prior expectation was implicit Q1/Q2 FY28 major OEM ramp. Now it's deferred to Q4/Q1, with lifecycle testing cycles running 2–3 years. Execution risk elevated; revenue materialization pushed into late FY28 or FY29. Core business momentum confirmed. Mid-double-digit growth guidance met; Q2 delivered 21.2% YoY, with automotive OEM +25% for four consecutive quarters. No surprise on the upside, but the track record is now credible. Margin corridor narrowed by execution gap. Stated 12–12.5% target narrowed to 'a range' with some quarters lower. Q2 OPM 10.6% signals management is comfortable missing the high end if input costs persist. Capex guidance deferred. No FY27/FY28 capex specifics given; management cited pending board approval. Phase-2 12 GWh capex decision deferred to when phase-1 hits 80% utilization (2–3 years hence). This removes a near-term upside catalyst.

The Bull-Bear Ledger
  • Core revenue +21% YoY; 4Q OEM growth +25% validates momentum

  • EBITDA margin +130 bps YoY; pricing power demonstrated

  • Balance sheet debt-free; strong cash generation for capex & investment

  • Q2 profit -18% QoQ; sequential softness not fully explained

  • OPM 10.6% vs 12–12.5% guided; margin corridor miss signals persistence of input lag

  • Lithium ramp slipped 2–3 quarters; major OEM revenue now Q4/Q1 FY28 or later

  • ₹5,352 Cr cumulative lithium investment; no quantified margin or ROI guidance given

  • Capex guidance deferred; phase-2 decision 2–3 years away

Risks, ranked by how much they should concern a holder

Lithium execution & validation delays

High

6 GWh plant live, but lifecycle testing is 2–3 years. Major OEM ramp now Q4/Q1 FY28 or later. If testing fails or customer wins slip further, the ₹5,352 Cr investment will take 4+ years to move the needle on earnings, or mark-to-market if demand disappoints.

Input cost volatility & pricing lag

High

Lead, LME, crude oil, rupee all remain volatile. Price hikes lag input spikes by 1–2 quarters. Q2 OPM 10.6% misses guided 12–12.5% target. If commodities stay elevated through H2, margin recovery is unlikely; further compression possible.

Sequential demand softness & cyclicality

Medium

Q2 revenue -4.3% QoQ, PAT -18% QoQ. Management blamed GST normalization but didn't rule out seasonal patterns repeating. Q3 could also soften. Lumpy order patterns in automotive (new model launches, OEM ordering cycles) and government tenders (railways, power) create visibility gaps.

China raw material supply disruption

Medium

Lithium hydroxide, cobalt exports from China could face restrictions. Exide planning 3-month inventory buffer, but higher holding could strain working capital. Supply-chain localization to 50–60% BoM target is 2–3 year roadmap; interim period carries supply risk.

Lead-acid volume decline as EV penetration accelerates

Medium

Two-wheeler & three-wheeler EV sales growing 30%+ CAGR. Lead-acid remains dominant for ICE parc (3–6 year replacement cycle), but structural volume headwinds will accelerate. Core business growth rate will decelerate over 3–5 years unless lithium offsets the decline.

How the Market is Positioned

The stock is down 38% from its all-time high of ₹620.35, now trading at ₹385.05. On the result announcement (Nov 4), the stock fell 1.6% on day 1 (delivery 78.2% of volume), then rebounded +4.52% by day 3. The rebound held, suggesting the market accepted the earnings narrative after initial disappointment. However, the stock remains below its 50-day simple moving average (₹393.82) and neutral in trend (RSI 56.6, between 40 and 70). Relative to the 52-week range (₹287–₹496.4), the stock is off its lows (+34% from low) but well below its highs (−37% from ATH). Ownership data shows FII holding stable at 10.63% (up +0.33pp QoQ) and DII at 19.30% (up +0.17pp QoQ), suggesting institutional appetite is cautious but not fleeing. Promoter holding remains at 45.99% with no change. The muted institutional activity suggests the market is waiting for lithium to prove out before re-engaging; the near-term narrative is one of core execution and margin recovery, not growth inflection.

What to Watch Next

Catalysts
  • 1 · Q3 FY27 lithium small-OEM ramp & sample validation updates (Dec 2026)

    Exide expects small OEM samples to be live by November/December. NMC lifecycle testing progress and LFP traction with emerging 2W players will be key. Any delays or customer feedback issues will further defer major OEM ramp.

  • 2 · Major OEM lithium cell production ramp timing (Q4 FY27 or Q1 FY28)

    Management guided Q4 or February for first major OEM production launches. This is the inflection point for lithium revenue materialization. Slippage beyond Q1 FY28 will reset the 2–3 year lithium timeline further out.

  • 3 · H2 FY27 margin trajectory & lead/rupee stabilisation (Oct–Mar 2027)

    Price hikes should begin flowing through by Q3. If input costs ease and pricing sticks, OPM could climb back toward 12% by H2. This will validate management's corridor guidance. If commodities remain sticky or pricing power wanes, the 10.6% could persist or compress further.

  • 4 · Phase-2 12 GWh capex board decision & timing (FY27/FY28)

    Management deferred phase-2 capex guidance to 'next quarter'. The trigger for phase-2 capex approval is 80% phase-1 utilization (2–3 years away per MD). Early signal on this timeline will clarify long-term lithium ambitions.

Exide's Q2 is a study in how momentum and margin can diverge. The core business is healthy—21% revenue growth, strong OEM traction, pricing power intact. But margin miss (150 bps below guided corridor), sequential profit decline (18% QoQ), and lithium timing slip (2–3 quarters deferred) temper the growth narrative. The market has priced in these risks; the stock is down 38% from its highs, and institutional flows are flat. The next 18 months are about margin recovery and core execution; the lithium inflection is 2–3 years out. Until lithium becomes a material revenue contributor, Exide is a steady-state battery play with event risk on execution and cyclical margin pressure. The number to track: operating margin. If Q3/Q4 FY27 OPM climbs back into the 12–12.5% corridor on the back of price hikes and input cost stabilisation, the near-term risk is contained. If it compresses further, the debate shifts from lithium timing to core business durability.

Informational and educational content only. Not investment advice.